Bioequivalence and Bioavailability Forum

Dear Helmut
This is my first post, although I've been an enthusiastic reader of the forum and a student with your presentations. Congratulations for this site/forum, which I think is very usefull for BE community.

A question that I've been tried to understand is that in a partial replicate design (for EU Scaled Average BE), is it possible to use 2 sequence (RTR and TRR, for example) or the study has to be design in a 3 sequence (RTR, TRR and RRT, according to FDA's progesterone example or according to data set on EMA Q&A document)? Does Phoenix enable a correct estimation of within subject variability and the calculation of the 90% CIs with this study design, or only SAS is possible to be used?

Best regards and wish of a pleasant 2014
Silva